Fidelis Capital Partners LLC Purchases 29,862 Shares of Pfizer Inc. $PFE

Fidelis Capital Partners LLC grew its position in Pfizer Inc. (NYSE:PFE) by 92.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,246 shares of the biopharmaceutical company’s stock after purchasing an additional 29,862 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Pfizer were worth $1,550,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PFE. Franklin Resources Inc. raised its position in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Vanguard Group Inc. raised its position in shares of Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. Neuberger Berman Group LLC increased its position in Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares during the period. Ameriprise Financial Inc. increased its position in Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after acquiring an additional 5,978,927 shares during the period. Finally, AQR Capital Management LLC increased its position in Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after acquiring an additional 5,202,884 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Trading Down 0.2%

Shares of Pfizer stock opened at $26.16 on Friday. The firm has a market capitalization of $149.07 billion, a PE ratio of 19.97 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company’s fifty day moving average price is $26.79 and its two-hundred day moving average price is $26.28. Pfizer Inc. has a 52-week low of $23.06 and a 52-week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent Biologics announced a global licensing and collaboration deal to research and develop 12 early-stage cancer medicines, with potential value of up to $10.5 billion. The agreement expands Pfizer’s oncology pipeline and could create long-term revenue opportunities. Reuters article
• Positive Sentiment: The companies also described the partnership as a strategic global collaboration covering ADCs and multi-specific antibodies, which suggests Pfizer is strengthening its next-generation cancer portfolio. PR Newswire article
• Positive Sentiment: Recent coverage also highlighted steady early-stage pipeline progress, including a new Phase 1 trial update, reinforcing the view that Pfizer has several development programs moving forward. TipRanks article
• Neutral Sentiment: Bank of America recently lifted its price target on Pfizer to $27 from $26 after stronger quarterly results, indicating slightly improved sentiment but still a cautious overall stance. Yahoo Finance article

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.